<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212015</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-06</org_study_id>
    <nct_id>NCT02212015</nct_id>
  </id_info>
  <brief_title>Evaluation of Votrient in Angiosarcoma</brief_title>
  <acronym>EVA</acronym>
  <official_title>Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helios Klinikum Berlin-Buch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universitaet Muenchen, Grosshadern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label phase II trial investigating the efficacy and safety of the investigational&#xD;
      combination of pazopanib and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label phase II trial investigating the efficacy and safety of the investigational&#xD;
      combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single&#xD;
      arm phase II study was designed to evaluate the clinical efficacy and safety of the&#xD;
      experimental combination of pazopanib with paclitaxel in the treatment of patients with&#xD;
      advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory&#xD;
      checks as defined in protocol, toxicity/adverse event assessment according Eastern&#xD;
      Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (=&#xD;
      day 1 of the next cycle).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to interim analysis' results and definitions fixed in protocol&#xD;
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression-free survival</measure>
    <time_frame>6 Month</time_frame>
    <description>Rate of progression-free survival after 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from start of treatment until death within study's actual observation time for OS (22 months).</time_frame>
    <description>Survival time of patient from start of treatment until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks during first 6 month then 12 weeks follow-up period until progression or death</time_frame>
    <description>Measurable skin lesions will be evaluated clinically and documented photographically, all other target lesions will be evaluated radiologically by CT or MRI according to RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>30 days after EOS of last patient</time_frame>
    <description>Number of patients in which adverse events occur during treatment according to Common Toxicity Criteria for Adverse Effects, Version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Pazopanib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib + Paclitaxel</intervention_name>
    <description>pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.</description>
    <arm_group_label>Pazopanib + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must provide written informed consent prior to performance of study-specific&#xD;
             procedures or assessments and must be willing to comply with treatment and follow-up.&#xD;
             Note: Procedures conducted as part of the subject's routine clinical management (e.g.,&#xD;
             blood count, imaging studies) and obtained prior to signing informed consent may be&#xD;
             utilized for screening or baseline purposes provided these procedures are conducted as&#xD;
             specified in the protocol.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Ability to swallow tablets&#xD;
&#xD;
          -  Histological confirmed angiosarcoma, primary and secondary angiosarcoma (e.g.&#xD;
             radiation-induced or angiosarcoma in chronical lymphedema) are eligible.&#xD;
&#xD;
          -  Tumor must be locally advanced (unresectable) or metastatic. A progression must be&#xD;
             documented within a 6-month period prior to screening.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≤ 2&#xD;
&#xD;
          -  At least one measurable skin lesion or one measurable radiological (CT or MRI) target&#xD;
             lesion (RECIST 1.1)&#xD;
&#xD;
          -  Adequate organ system function as described in protocol&#xD;
&#xD;
          -  A female is eligible to enter and participate in this study if she is either of non&#xD;
             childbearing potential (defined in protocol) or childbearing potential with negative&#xD;
             pregnancy test within 2 weeks prior to the first dose of study drug and agrees to use&#xD;
             adequate contraception (as defined in protocol) during the study and for 30 days after&#xD;
             the last dose of study drug.&#xD;
&#xD;
          -  All sexually active male patients must agree to use adequate methods of birth control&#xD;
             (see protocol) throughout the study and for 30 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who need an active treatment for another malignant disease other than&#xD;
             angiosarcoma&#xD;
&#xD;
          -  Prior treatment with taxane within the last 12 months before study entry&#xD;
&#xD;
          -  History or clinical evidence of central nervous system (CNS) metastases or&#xD;
             leptomeningeal sarcomatosis.(see protocol)&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding (see protocol)&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             investigational product (see protocol)&#xD;
&#xD;
          -  Presence of uncontrolled infection&#xD;
&#xD;
          -  QT prolongation interval (QTc) &gt; 480 msec.&#xD;
&#xD;
          -  Clinically significant cardiovascular disorders within the past 6 months&#xD;
&#xD;
          -  Major surgery or trauma within 28 days prior to first dose of investigational product&#xD;
             and/or presence of any non-healing wound, fracture, or ulcer&#xD;
&#xD;
          -  Poorly controlled hypertension (see protocol)&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels&#xD;
&#xD;
          -  Uncontrolled seizures, disorders of the CNS or psychiatric disorders which may put&#xD;
             patient safety at risk, prevent giving informed consent or impact the patient's&#xD;
             compliance with the use of study medication&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients who are not able or not willing to interrupt the intake of medications that&#xD;
             are not allowed according to study protocol for at least 14 days before start of study&#xD;
             medication and for the whole study period&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 14 days before start of study medication&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt; grade 1 and/or that is&#xD;
             progressing in severity, except alopecia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hohenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim / Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios-Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Campus Großhadern</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gisg.de</url>
    <description>German Interdisciplinary Sarcoma Group</description>
  </link>
  <link>
    <url>http://www.sarcoma.at</url>
    <description>Sarcoma Platform Austria</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Peter Hohenberger</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 4, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

